Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for AKBA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 -4.079M
March 31, 2026 -0.062M
December 31, 2025 -7.877M
September 30, 2025 -0.077M
June 30, 2025 -0.126M
March 31, 2025 0.154M
December 31, 2024 -0.002M
September 30, 2024 -0.002M
June 30, 2024 -0.029M
March 31, 2024 0.00
December 31, 2023 0.00
September 30, 2023 0.00
June 30, 2023 0.00
March 31, 2023 0.00
December 31, 2022 0.00
September 30, 2022 0.00
June 30, 2022 0.00
March 31, 2022 -0.114M
December 31, 2021 0.00
September 30, 2021 0.00
June 30, 2021 20.00M
March 31, 2021 19.94M
December 31, 2020 59.68M
September 30, 2020 -49.94M
June 30, 2020 -50.00M
Date Value
March 31, 2020 0.245M
December 31, 2019 22.28M
September 30, 2019 24.39M
June 30, 2019 54.03M
March 31, 2019 110.47M
December 31, 2018 16.72M
September 30, 2018 11.01M
June 30, 2018 -3.568M
March 31, 2018 12.43M
December 31, 2017 -8.308M
September 30, 2017 -44.96M
June 30, 2017 -31.69M
March 31, 2017 -92.30M
December 31, 2016 22.31M
September 30, 2016 45.57M
June 30, 2016 29.79M
March 31, 2016 -84.96M
December 31, 2015 1.638M
September 30, 2015 -14.46M
June 30, 2015 -4.276M
March 31, 2015 3.405M
December 31, 2014 -7.637M
September 30, 2014 -40.00M
June 30, 2014 -23.07M
March 31, 2014 5.358M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Emergent BioSolutions, Inc. -52.30M
Exelixis, Inc. 91.43M
ADMA Biologics, Inc. -2.256M
Arcutis Biotherapeutics, Inc. -15.22M
Relay Therapeutics, Inc. -353.03M